Clinical trials: Local Recurrence
Head and Neck Neoplasms, Neoplasm Recurrence, Local
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent…
- Conditions
- Head and Neck Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
- Trial name
- NCT00401323
- Testing
- docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU)
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 568 people
- Sponsor
- Sanofi
Head and Neck Neoplasms, Skin Neoplasms
Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer
This study is an open, non- randomized, phase I, dose-escalating study to evaluate the safety and tolerance of Amphinex based PCI of bleomycin in patients with local recurrent or advanced/metastatic, cutaneous or sub-cutaneous…
- Trial name
- NCT00993512
- Testing
- Amphinex (TPCS2a), Bleomycin, Illumination with CeramOptec laser
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- PCI Biotech AS
Glioblastoma, Anaplastic Astrocytoma
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade…
- Trial name
- NCT00431561
- Testing
- AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV
- Where
- 36 sites in Austria, Georgia and 4 more
- Volunteers
- 141 people
- Sponsor
- Isarna Therapeutics GmbH
Cutaneous or Sub-cutaneous Malignancies
Dose Escalating Study for Amphinex-based PCI of Bleomycin.
The primary goal of this extension study is to further investigate the tolerability and efficacy in a phase I setting in order to see whether lower doses than the initial study dose of 0.25 mg/kg bw Amphinex in Amphinex-based PCI…
- Trial name
- NCT01872923
- Testing
- Amphinex, Bleomycin, Laser
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- PCI Biotech AS
Liver Metastases, Colorectal Neoplasms
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
The purpose of the study is to assess the overall survival and progression free survival of patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of Colorectal Cancer with recurrent liver…
- Conditions
- Liver Metastases, Colorectal Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local
- Trial name
- NCT00440310
- Testing
- Talaporfin sodium, Percutaneous placement of device in liver metastases, Interstitial light emitting diodes
- Where
- 57 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 483 people
- Sponsor
- Light Sciences Oncology
Recurrent Head and Neck Cancer
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
Primary Objective: The primary objective of the study is to evaluate the safety of repeat administration of a dose level of Ad/PNP plus fludarabine phosphate (F-araAMP) which demonstrated anti-tumor activity in patients with…
- Trial name
- NCT03754933
- Testing
- Ad/PNP, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- GeoVax, Inc.
Healthy
Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous Ulcers
This trial is conducted in China. The purpose is to evaluate the efficacy, Pharmacokinetics (PK) profile, immunogenicity and safety of GB001 recombinant peptide spray in adults with mild recurrent aphthous ulcer.
- Trial name
- NCT06429566
- Testing
- GB001 recombinant peptide spray low dose group、high dose group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Echon Biopharm Limited
Squamous Cell Cancer
Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
The purpose of this open-label, randomized, controlled, Phase 1/2 study of the integrin inhibitor cilengitide is to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin…
- Trial name
- ADVANTAGE (NCT00705016)
- Testing
- Cilengitide 2000 mg once weekly, Cilengitide 2000 mg twice weekly, Cetuximab
- Where
- 37 sites in Austria, Belgium and 7 more
- Volunteers
- 184 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Liver Neoplasms, Neoplasm Metastasis
Study of NS-9 in Patients With Liver Metastases
This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor.
- Conditions
- Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
- Trial name
- NCT00094003
- Testing
- NS-9 [Poly I: Poly C]
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NS Pharma, Inc.
Glioblastoma Multiforme, Brain Neoplasms
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma
OncoGel™ is a new, experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel™) over a long period of time.
- Trial name
- NCT00479765
- Testing
- OncoGel (ReGel/Paclitaxel)
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Boston Scientific Corporation
Head and Neck Cancer
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary…
- Trial name
- NCT00198315
- Testing
- Medpulser electroporation with Bleomycin, Tumor surgical excision
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Inovio Pharmaceuticals
Carcinoma, Transitional Cell Carcinoma
Efficacy and Safety of UGN-101 in Recurrent Patients
This trial is designed to evaluate the efficacy and safety of UGN-101 administered to the upper urinary tract (UUT) in patients who were treated in Trial TC-UT-03, found to be a complete response (CR) at the Primary Disease…
- Conditions
- Carcinoma, Transitional Cell Carcinoma, Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- Retreatment (NCT04006691)
- Testing
- UGN-101 instillations
- Where
- 5 sites in United States, Israel
- Sponsor
- UroGen Pharma Ltd.
Non Squamous Non Small Cell Lung
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more effective as compared to placebo in combination…
- Trial name
- NCT02766140
- Testing
- SHR1020 plus Docetaxel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Biochemically Recurrent Prostate Cancer
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy…
- Trial name
- ARASTEP (NCT05794906)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 985 people
- Sponsor
- Bayer
Breast Cancer, Early Breast Cancer
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease…
- Trial name
- CAMBRIA-2 (NCT05952557)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 661 sites in United States, Argentina and 42 more
- Volunteers
- 5,511 people
- Sponsor
- AstraZeneca
Malignant Pleural Mesotheliomas
Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
This example study evaluates locoregional allogeneic dual-target mesothelin/FAP CAR-NK cells in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma.
- Trial name
- DUAL-MESO-NK (NCT07510815)
- Testing
- EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Carcinoma, Hepatocellular
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
- Trial name
- STORM (NCT00692770)
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 199 sites in United States, Argentina and 26 more
- Volunteers
- 1,114 people
- Sponsor
- Bayer
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Prostate Cancer
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for prostate cancer.
- Trial name
- NCT05617040
- Testing
- ChAdOx1-PCAQ, MVA-PCAQ
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Barinthus Biotherapeutics